Literature DB >> 34009286

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.

Benedikt Lohr1, Dirk Niemann2, Jens Verheyen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34009286     DOI： 10.1093/cid/ciab392

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

Review 1.  Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency.

Authors:  Nathan M Markarian; Gaël Galli; Dhanesh Patel; Mark Hemmings; Priya Nagpal; Albert M Berghuis; Levon Abrahamyan; Silvia M Vidal
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

2.  Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.

Authors:  Yotam Bronstein; Amos Adler; Haytham Katash; Ora Halutz; Yair Herishanu; Katia Levytskyi
Journal:  J Med Virol       Date:  2021-11-13       Impact factor: 20.693

3.  Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review.

Authors:  Daniele Focosi; Fabrizio Maggi; Massimo Franchini; Scott McConnell; Arturo Casadevall
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

4.  Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.

Authors:  Arick P Sabin; Craig S Richmond; Paraic A Kenny
Journal:  Diagn Microbiol Infect Dis       Date:  2022-02-03       Impact factor: 2.803

Review 5.  A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

6.  Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera.

Authors:  Martina Brandolini; Giorgio Dirani; Francesca Taddei; Silvia Zannoli; Agnese Denicolò; Valentina Arfilli; Arianna Battisti; Martina Manera; Andrea Mancini; Laura Grumiro; Maria Michela Marino; Giulia Gatti; Michela Fantini; Simona Semprini; Vittorio Sambri
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

7.  De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients.

Authors:  Lacy M Simons; Egon A Ozer; Stephanie Gambut; Taylor J Dean; Li Zhang; Pavan Bhimalli; Jeffrey R Schneider; João I Mamede; Michael G Ison; Reem Karmali; Leo I Gordon; Ramon Lorenzo-Redondo; Judd F Hultquist
Journal:  Transpl Infect Dis       Date:  2022-07-28

Review 8.  The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.

Authors:  Daniele Focosi; Scott McConnell; Arturo Casadevall
Journal:  Drug Resist Updat       Date:  2022-10-03       Impact factor: 22.841

9.  Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation.

Authors:  Hye Kyung Lee; Ludwig Knabl; Ludwig Knabl; Manuel Wieser; Anna Mur; August Zabernigg; Jana Schumacher; Norbert Kaiser; Priscilla A Furth; Lothar Hennighausen
Journal:  medRxiv       Date:  2021-05-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.